Agios Pharm (NASDAQ:AGIO) — Market Cap & Net Worth
Market Cap & Net Worth: Agios Pharm (AGIO)
Agios Pharm (NASDAQ:AGIO) has a market capitalization of $1.71 Billion ($1.71 Billion) as of June 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6834 globally and #2064 in its home market, demonstrating a 2.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Agios Pharm's stock price $29.46 by its total outstanding shares 59471609 (59.47 Million). Review AGIO total liabilities to assess the company's total debt and financial obligations.
Agios Pharm Market Cap History: 2015 to 2026
Agios Pharm's market capitalization history from 2015 to 2026. Data shows change from $3.86 Billion to $1.75 Billion (-7.58% CAGR).
Index Memberships
Agios Pharm is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.08 Trillion | 0.16% | #20 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.07% | #178 of 976 |
|
NASDAQ Composite
IXIC
|
$40.95 Trillion | 0.00% | #745 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.10% | #113 of 263 |
Weight: Agios Pharm's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Agios Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Agios Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
29.96x
Agios Pharm's market cap is 29.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.48 Billion | $69.89 Million | -$198.47 Million | 35.51x | N/A |
| 2017 | $3.40 Billion | $43.01 Million | -$314.67 Million | 79.05x | N/A |
| 2018 | $2.74 Billion | $94.39 Million | -$346.03 Million | 29.05x | N/A |
| 2019 | $2.84 Billion | $117.91 Million | -$411.47 Million | 24.08x | N/A |
| 2020 | $2.58 Billion | $203.20 Million | -$327.37 Million | 12.68x | N/A |
| 2021 | $1.95 Billion | $41.41K | $1.60 Billion | 47207.90x | 1.22x |
| 2022 | $1.67 Billion | $14.24 Million | -$231.80 Million | 117.27x | N/A |
| 2023 | $1.32 Billion | $26.82 Million | -$352.09 Million | 49.38x | N/A |
| 2024 | $1.95 Billion | $36.50 Million | $673.73 Million | 53.54x | 2.90x |
| 2025 | $1.62 Billion | $54.03 Million | -$412.78 Million | 29.96x | N/A |
Competitor Companies of AGIO by Market Capitalization
Companies near Agios Pharm in the global market cap rankings as of June 15, 2026.
Key companies related to Agios Pharm by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
Agios Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Agios Pharm's market cap moved from $3.86 Billion to $ 1.75 Billion, with a yearly change of -7.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.75 Billion | +8.23% |
| 2025 | $1.62 Billion | -17.16% |
| 2024 | $1.95 Billion | +47.55% |
| 2023 | $1.32 Billion | -20.69% |
| 2022 | $1.67 Billion | -14.57% |
| 2021 | $1.95 Billion | -24.14% |
| 2020 | $2.58 Billion | -9.26% |
| 2019 | $2.84 Billion | +3.56% |
| 2018 | $2.74 Billion | -19.35% |
| 2017 | $3.40 Billion | +37.00% |
| 2016 | $2.48 Billion | -35.72% |
| 2015 | $3.86 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of Agios Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.71 Billion USD |
| MoneyControl | $1.71 Billion USD |
| MarketWatch | $1.71 Billion USD |
| marketcap.company | $1.71 Billion USD |
| Reuters | $1.71 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more